Quest Diagnostics Incorporated (NYSE:DGX) Shares Bought by Keybank National Association OH

Keybank National Association OH boosted its stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 25.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,917 shares of the medical research company's stock after acquiring an additional 1,409 shares during the period. Keybank National Association OH's holdings in Quest Diagnostics were worth $1,170,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at about $323,000. Smartleaf Asset Management LLC grew its holdings in shares of Quest Diagnostics by 17.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 742 shares of the medical research company's stock worth $112,000 after acquiring an additional 110 shares during the period. Jones Financial Companies Lllp increased its stake in Quest Diagnostics by 117.4% in the 4th quarter. Jones Financial Companies Lllp now owns 1,848 shares of the medical research company's stock valued at $279,000 after purchasing an additional 998 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in Quest Diagnostics during the fourth quarter worth $54,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Quest Diagnostics by 4.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 736,433 shares of the medical research company's stock worth $111,098,000 after purchasing an additional 28,333 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on DGX shares. Redburn Atlantic began coverage on Quest Diagnostics in a research note on Wednesday, April 2nd. They set a "buy" rating and a $195.00 price target for the company. Wall Street Zen cut shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Saturday, June 7th. Redburn Partners set a $195.00 price target on shares of Quest Diagnostics in a report on Wednesday, April 2nd. Evercore ISI raised their price objective on shares of Quest Diagnostics from $175.00 to $180.00 and gave the stock an "in-line" rating in a research note on Wednesday, April 23rd. Finally, Truist Financial upped their target price on Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday, April 23rd. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics has a consensus rating of "Moderate Buy" and an average target price of $185.73.

Quest Diagnostics Stock Down 0.9%

Shares of DGX stock traded down $1.66 during trading hours on Monday, reaching $174.46. The company had a trading volume of 86,852 shares, compared to its average volume of 988,094. The company has a market capitalization of $19.48 billion, a P/E ratio of 22.02, a price-to-earnings-growth ratio of 2.47 and a beta of 0.49. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.31 and a current ratio of 1.44. Quest Diagnostics Incorporated has a twelve month low of $136.99 and a twelve month high of $182.38. The stock's fifty day simple moving average is $176.47 and its 200 day simple moving average is $167.99.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a net margin of 8.81% and a return on equity of 15.11%. The company had revenue of $2.65 billion during the quarter, compared to analysts' expectations of $2.63 billion. As a group, sell-side analysts expect that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 21st. Shareholders of record on Monday, July 7th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 1.83%. The ex-dividend date of this dividend is Monday, July 7th. Quest Diagnostics's dividend payout ratio is currently 40.46%.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Mark E. Delaney sold 874 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $175.72, for a total transaction of $153,579.28. Following the transaction, the senior vice president owned 8,372 shares of the company's stock, valued at approximately $1,471,127.84. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.16% of the company's stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.